WuXi AppTec Says Findings of U.S. Draft Bill Against Company Aren't Accurate
By P.R. Venkat
Chinese company WuXi AppTec said alleged findings by a U.S. draft bill against it were neither legitimate nor accurate and that its business wouldn't pose security risks for any country.
WuXi AppTech abides by laws and regulations in the countries in which it operates, including in both China and the U.S., the biotech company said late Friday.
The Chinese company's statement was in response to a proposed bill introduced by U.S. lawmakers barring federal contracts with Beijing Genomics Institute and some Chinese biotech entities due to alleged connections with the People's Liberation Army.
Shares of the WuXi family of companies tumbled on Friday on concerns the proposed bill would block the U.S. government from doing business with certain Chinese biotechnology companies.
The WuXi companies were among those named in the bill. Lawmakers said WuXi AppTec "presents a national security threat to the United States," naming examples of its connections with the military. It said WuXi Biologics' chief executive was once an adjunct professor at China's Academy of Military Medical Sciences.
In a separate filing Monday, WuXi Biologics said that the draft bill contained a misleading description of the background of its CEO, Zhisheng Chen.
"He has neither worked for the Academy of Military Medical Sciences or any military-affiliated institution nor has he received compensation from military-affiliated institutions," WuXi Biologics said.
Write to P.R. Venkat at venkat.pr@wsj.com
(END) Dow Jones Newswires
January 28, 2024 19:16 ET (00:16 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Q4 Stock Market Outlook: Where We See Opportunities for Investors
-
Markets Brief: Non-Farm Payrolls in the Spotlight Again
-
6 Top-Performing Large-Growth Funds
-
What’s the Difference Between the CPI and PCE Indexes?
-
This Cheap Stock Is Still a Buy Even After 50% Rally
-
10 Top-Performing Dividend Stocks of Q3 2024
-
33 Undervalued Stocks
-
Communication Services: Cable’s Broadband Dominance Isn’t as Strong as It Once Was
-
Technology: Strength Continues, With Software Presenting the Best Buying Opportunities
-
Best- and Worst-Performing Stocks of Q3 2024
-
Top Stocks to Own From the Best Fund Managers
-
2 Cheap Stocks Top Managers Have Been Buying